Small Cell Lung Cancer
Advertisement
Study investigators say the combination "showed promising efficacy" in patients with relapsed small cell lung cancer.
A distributed clinical trial is analyzing diet and exercise patterns in young people with lung cancer.
Christopher Seder, MD, discusses the database and how it can be used for research, quality improvement, and risk ...
The recommendation is based on results from the phase 3 ADRIATIC trial.
The subcutaneous injection is now approved for all adult indications of the intravenous formulation of atezolizumab
The initiative aims to increase biomarker testing rates in communities most impacted by lung cancer disparities.
The TROPiCS-03 trial, a multicohort, open-label basket study, is assessing the antibody-drug conjugate in solid tumors.
The foundation's 2024 Scientific Grant Program awards mark the "largest single-year investment in its history.”
The Breakthrough Therapy Designation is based on results from the ES-SCLC cohort in the global phase 2 TROPiCS-03 study.
Lauren Averett Byers, MD, will be honored with the award during the TAMEST Annual Conference in February.
The phase 2 expansion portion of the trial will enroll approximately 50 patients at 10 to 15 sites in the United States.
Investigators evaluated the efficacy of durvalumab in the randomized, double-blind, placebo-controlled ADRIATIC trial.
For patients with Schlafen 11-positive ES-SCLC, atezolizumab plus talazoparib showed an PFS improvement after chemotherapy.
Researchers conducted an extensive analysis of PM2.5 exposure based on residential history, satellite data, and more.
Learn what the global survey showed about the rates of biomarker testing and the remaining barriers to implementation.
Michael R. Gieske, MD, discusses the lung cancer screening initiative, which has been recognized on a national level.
The registry, launched by the Florez Lab in 2023, is collecting data from around the world.
Indoor air pollutants can come from multiple sources and can be risk factors for developing lung cancer.
Officials plan to submit a supplemental New Drug Application for the use of the combination therapy in this setting.
Shirish M. Gadgeel, MD, shares how treatment options and patient outcomes have evolved since he began practicing.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.